CompletedPhase 3

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

United States300 participantsStarted 2024-06-24

Plain-language summary

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Body Mass index (BMI) greater than or equal to (≥) 30.0 kilogram per meter square (kg/m\^2) or
✓. BMI ≥27.0 kg/m2 with the presence of at least one obesity related complication including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

What they're measuring

Relative change in body weight

Timeframe: From baseline (week 0) to end of treatment (week 68)

Achievement of ≥5% weight reduction

Timeframe: From baseline (week 0) to end of treatment (week 68)

Trial details

NCT IDNCT06388187

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-04-22

View on ClinicalTrials.gov More Obesity trials